Bernstein Upgrades Campbell as GLP-1 Users Boost Soup Sales

Bernstein Research has upgraded its rating on Campbell Soup Company, citing a surge in soup sales driven by the growing popularity of glucagon-like peptide-1 (GLP-1) medications. These medications, commonly used for weight management and diabetes treatment, have been found to increase appetite suppression and alter food preferences.

Campbell Soup’s product portfolio, including its iconic soups, is well-suited to cater to the dietary needs of individuals taking GLP-1 medications. The company’s soups often provide a convenient, low-calorie, and flavorful meal option, aligning with the dietary preferences of those using these medications.

The analyst firm highlighted that Campbell Soup was among the first major food companies to recognize the potential impact of GLP-1 drugs on consumer behavior. This foresight has positioned the company to benefit from the growing market for healthier, convenient food options.

While soup sales have declined in recent years, the trend has reversed in 2024, coinciding with the increased use of GLP-1 medications. This suggests a strong correlation between the two factors, indicating that GLP-1 users are more likely to choose soup as a meal option.

The analyst firm’s upgrade reflects a positive outlook for Campbell Soup’s future performance. The company’s ability to capitalize on the growing demand for healthier food options, driven by the popularity of GLP-1 medications, is seen as a significant catalyst for its growth.